Back to home
Health·

Andorra Launches Annual Flu Vaccination Campaign Targeting Elderly and At-Risk Groups

Andorra's flu shot drive emphasises protection for seniors and high-risk individuals through CAP appointments and prescriptions. Last year's effort reached over 8,000 amid consistent engagement.

Key Points

  • Campaign runs from Monday to 31 January 2026; requires appointments at primary care centres.
  • Eligible: over-60s, under-60s with risk factors (need prescription), healthcare workers, essential staff.
  • Last season delivered 8,091 doses; steady participation post-pandemic.
  • Parallel RSV strategy includes nirsevimab for infants and vaccines for over-60s in care centres.

Andorra's annual influenza vaccination campaign got underway on Monday, targeting people aged 60 and over as well as those under 60 with risk factors. The drive will run until 31 January 2026 and requires advance appointments at primary care centres (CAPs), with those under 60 needing a prescription from their primary care doctor.

Health authorities are following the same administration protocols as in previous years across CAPs, designated facilities and sites suited to vulnerable groups. Eligible recipients also include people who could transmit the virus to at-risk populations, such as workers at healthcare and sociosanitary centres, essential community service professionals, and both inmates and staff at the Centre Penitenciari.

Last season's campaign, from 6 October 2025 to 31 January 2026, delivered 8,091 doses—3,809 to men and 4,282 to women. No uptake projections have been released for this year, though participation has held steady since the pandemic amid sustained public awareness.

The symbolic launch took place at the CAP in Sant Julià de Lòria. Officials emphasise the campaign's role in protecting elderly and vulnerable residents from aggressive seasonal flu strains during winter.

In parallel, the Health Ministry is maintaining its dual strategy against respiratory syncytial virus (RSV) to bolster defences for the most at-risk. This includes preventive treatment (nirsevimab) for newborns and children under two with risk factors, alongside vaccinations for those over 80 and adults over 60 in sociosanitary centres—now part of the adult vaccination calendar. Such measures aim to curb bronchiolitis and pneumonia.

Share the article via